FRIENDSWOOD, Texas — December 12, 2025 — Castle Biosciences, Inc., a diagnostics company advancing precision medicine in gastroenterology, announced the publication of a systematic review and meta-analysis (SRMA) confirming that the TissueCypher® Barrett’s Esophagus test outperforms traditional pathology and clinical risk factors alone in identifying patients at increased risk of developing esophageal cancer. Published in a peer-reviewed clinical journal, the analysis consolidates evidence from multiple studies and reinforces TissueCypher’s role as a clinically validated, risk-stratification tool for patients with Barrett’s esophagus.
Science Significance
Scientifically, the SRMA represents one of the highest levels of clinical evidence, synthesizing results from six independent, published studies to assess TissueCypher’s predictive performance. The analysis demonstrates that patients with high-risk TissueCypher results were 6.7 times more likely to progress to high-grade dysplasia (HGD) or esophageal adenocarcinoma (EAC) within five years compared with low-risk patients. By leveraging an AI-driven spatialomics approach that detects molecular signatures preceding histologic change, TissueCypher advances beyond conventional microscopy, enabling earlier and more precise identification of malignant progression risk across non-dysplastic, indefinite-for-dysplasia, and low-grade dysplasia populations.
Regulatory Significance
From a regulatory and quality perspective, the findings strengthen the clinical validation foundation required for adoption of advanced diagnostic tests in regulated healthcare environments. SRMAs are widely regarded as robust evidence supporting clinical utility, reproducibility, and generalizability. The demonstrated consistency across multiple cohorts supports TissueCypher’s role in risk-aligned clinical decision-making, aligning with expectations for laboratory-developed tests and regulated diagnostics operating under rigorous clinical and quality standards. The evidence base also supports confidence among clinicians and health systems seeking validated tools that complement guideline-based care pathways.
Business Significance
Advertisement
For Castle Biosciences, the publication reinforces TissueCypher as a differentiated clinical asset within the growing precision diagnostics market. Demonstrating superior performance relative to pathology alone strengthens the test’s value proposition to clinicians, health systems, and payers, particularly in an era focused on outcomes-driven care. With validation now supported by 17 peer-reviewed publications and data from more than 8,000 patients, TissueCypher is positioned as a scalable diagnostic solution capable of driving broader clinical adoption while supporting Castle’s strategy to expand its gastroenterology diagnostics portfolio.
Patients’ Significance
For patients with Barrett’s esophagus, the implications are substantial. Traditional surveillance strategies often result in over-treatment for some patients and delayed intervention for others due to limited predictive accuracy. TissueCypher enables personalized risk assessment, helping identify patients who may benefit from earlier therapeutic intervention while sparing low-risk individuals from unnecessary procedures and anxiety. By aligning surveillance intensity with individualized risk, the test has the potential to improve outcomes, reduce procedural burden, and enhance quality of life, while supporting earlier prevention of esophageal cancer.
Policy Significance
At a policy level, the findings align with broader healthcare priorities emphasizing evidence-based, risk-stratified care and efficient use of medical resources. Diagnostic tools that reliably identify high-risk patients support value-based care models, reducing unnecessary interventions while focusing attention on those most likely to benefit. The SRMA also highlights the growing role of advanced analytics and AI-enabled diagnostics in shaping future clinical guidelines and reimbursement discussions, reinforcing the importance of policies that support innovation grounded in rigorous clinical evidence.
The systematic review and meta-analysis validating TissueCypher® marks a significant milestone in the evolution of precision diagnostics for esophageal cancer prevention. By demonstrating consistent, superior performance across multiple studies, Castle Biosciences provides compelling evidence that molecular risk stratification can meaningfully enhance traditional clinical assessment. For the cGxP.wire audience, the announcement exemplifies how rigorous clinical science, quality-driven validation, and translational diagnostics are converging to improve patient management and outcomes in gastroenterology.
Source: Castle Biosciences, Inc. press release
